 |
194 Diseases |  |
7 Trials |
|
7 Trials |  |
234 News |  |
| «1234» |
- Triapine (3-AP) / Vion
Targeting RRM2 by triapine sensitizes glioblastoma to radiotherapy (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_531;
Our results demonstrate that RRM2 is overexpressed in glioblastoma and targeting RRM2 with triapine enhances radiation-induced DNA damage leading to radiosensitization of glioblastoma cells. Our findings suggest that triapine is a promising agent for the sensitization of glioblastoma to radiotherapy.
- Triapine (3-AP) / Vion
Effect of 3AP on neuroendocrine tumor cell proliferation, apoptosis and activation of DNA repair pathway (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_525;
Our results demonstrated rapid and dose dependent decrease in cyclin D1 expression after Triapine treatment, dose-dependent activation of DNA-PK, the key component of the non-homologous end joining pathway and significant increase in the radiosensitivity of each of the tumor cell lines. In conclusion, our findings provide a rationale for inclusion of Triapine as a radiosensitizer in combination with PRRT in treating NETs.
- Triapine (3-AP) / Vion
Improved activity and paraptosis-induction of anticancer thiosemicarbazones requires high copper(II) complex stability and slow reduction kinetics (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_1295;
Triapine, which is currently tested in a clinical phase III trial, is the best-studied thiosemicarbazone (TSC) for anticancer therapy...This intracellular stability of complexes, affects their mechanism of action as well as cell death induction. Overall, this study points out the importance of the redox parameters in order to understand and predict the TSC anticancer activity as well as their mechanism of action and, thereby, will pave the way for the development of improved anticancer agents.
- | Triapine (3-AP) / Vion
Journal: Reactivity of Cu(ii)-, Zn(ii)- and Fe(ii)-thiosemicarbazone complexes with glutathione and metallothionein: from stability to dissociation to transmetallation. (Pubmed Central) - May 15, 2020
Herein, we study the complexes of copper(ii), zinc(ii) and iron(ii) with three TSCs, PT, 3-AP (triapine) and Dp44mT, (latter two are currently in clinical trials), concerning their reactivity with glutathione (GSH) and Zn7-metallothionein (Zn7MT-1, 2 and 3)...These results indicate that GSH and Zn7MT may be important factors in the fate of Cu(ii)- and Zn(ii)-TSCs. In particular, for Cu, its chemistry is complex, and these reactions may also occur for other families of Cu-complexes used in cancer treatment or for other applications.
- | Triapine / Vion
Journal: A novel triapine derivative induces copper-dependent cell death in hematopoietic cancers. (Pubmed Central) - Mar 4, 2020
Remarkedly, 10 showed good bioavailability and inhibited tumor growth in mouse xenograft models. Taken together, our study identifies compound 10 as a copper-dependent anti-tumor agent, which may be applied to the treatment of hematopoietic cancers.
- Triapine (3-AP) / Vion, Lutathera (lutetium Lu 177 dotatate) / Novartis
[VIRTUAL] Etctn 10388: A phase I trial of triapine and lutetium Lu 177 dotatate in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). (Poster Board 268) - Feb 27, 2020 - Abstract #ASCO2020ASCO_546;
In addition, the study will correlate clinical outcome with baseline somatostatin receptor density, somatic tumor mutations and germline mutations. Research Funding: NCI CTEP
- Triapine / Vion, cisplatin / Generic mfg.
Enhancing the anticancer potency of titanium(IV) chemical transferrin mimetic complexes by exploring the synergism of co-treatment with triapine and cisplatin (112B, Pennsylvania Convention Center) - Feb 13, 2020 - Abstract #ACSSp2020ACS_Sp_2370;
Results revealed both additive and near synergistic effects among combinations. Additionally, we studied the complex formation processes of triapine with Ti(IV) by pH-potentiometric and UV-Vis spectrophotometric measurements and disclose a new transmetalation drug strategy to create Ti(IV) iron chelator compounds that transform intracellular labile Fe(III) into cytotoxic Fe(II) and that specifically inhibit the RNR enzyme at its diiron activation site.
- | Triapine / Vion
Journal: Concentration of Fe(3+)-Triapine in BEAS-2B Cells. (Pubmed Central) - Jan 21, 2020
Here, it is shown that iron from purified Fe-transferrin is transferred to Triapine after the addition of ascorbate. To our knowledge, this is the first time that the EPR method has been used to determine the concentration of an iron antitumor agent in cells.
- | Triapine (3-AP) / Vion, Lutathera (lutetium Lu 177 dotatate) / Novartis
New P1 trial: ETCTN 10388: Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors (clinicaltrials.gov) - Jan 21, 2020
P1, N=29, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- Triapine / Vion, cisplatin / Generic mfg.
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer (Texan E/4th Level) - Jan 7, 2020 - Abstract #NRG2020NRG_367;
- Triapine / Vion, cisplatin / Generic mfg.
A randomized phase II trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage IB2, stage II, IIIB, or IVA Cancer of the uterine cervix or Stage II-IVA vaginal cancer (Texan E/4th Level) - Jan 7, 2020 - Abstract #NRG2020NRG_340;
Accrual 101/188 (53.7%) iii. Amendment to CTEP re: increase in accrual size and transition to Randomized phase 3
- | Triapine / Vion
Journal: The thiosemicarbazone MeNNMe induces paraptosis by disrupting the ER thiol redox homeostasis based on protein disulfide isomerase inhibition. (Pubmed Central) - Dec 21, 2019
Due to their high biological activity, thiosemicarbazones have been developed for treatment of diverse diseases, including cancer, resulting in multiple clinical trials especially of the lead compound Triapine...Subsequently, we uncover that the copper complex of MeNNMe (a supposed intracellular metabolite) inhibits the ER-resident protein disulfide isomerase, resulting in a specific form of ER stress based on disruption of the Ca and ER thiol redox homeostasis. Our findings indicate that compounds like MeNNMe are of interest especially for the treatment of apoptosis-resistant cancer and provide new insights into mechanisms underlying drug-induced paraptosis.
- | Triapine / Vion
Journal: Synthesis and biological evaluation of biotin-conjugated anticancer thiosemicarbazones and their iron(III) and copper(II) complexes. (Pubmed Central) - Dec 21, 2019
Nonetheless, the metal-free biotin-conjugate of Triapine revealed distinct activity in a colon cancer mouse model upon oral application comparable to Triapine. Therefore, this type of biotin-conjugated thiosemicarbazone is of interest for further synthetic strategies and biological studies.
- || Triapine (3-AP) / Vion
Clinical, P2 data, Journal: Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for Locally Advanced Stage Uterine Cervix or Vaginal Cancers. (Pubmed Central) - Nov 5, 2019
P2, P3
In conclusion, the addition of triapine to cisplatin-radiotherapy improved the rate of metabolic complete response in patients with advanced-stage uterine cervix or vaginal cancers without significant toxicity. A phase III trial adequately powered to evaluate progression-free and overall survival is underway (NCT02466971).
- | Triapine / Vion
Journal: New Water-Soluble Copper(II) Complexes with Morpholine-Thiosemicarbazone Hybrids: Insights into the Anticancer and Antibacterial Mode of Action. (Pubmed Central) - Oct 29, 2019
The lead proligands and Cu(II) complexes displayed higher antiproliferative activity in cancer cells than triapine...Insights into the processes controlling intracellular accumulation and mechanism of action were investigated for 2 and 5, including the role of ribonucleotide reductase (RNR) inhibition, endoplasmic reticulum (ER) stress induction and regulation of other cancer signaling pathways. Their ability to moderately inhibit R2 RNR protein in the presence of DTT is likely related to iron chelating properties of the proligands liberated upon reduction.
- | Triapine / Vion
Journal: Ribonucleotide reductase subunit M2 as a novel target for clear-cell renal cell carcinoma. (Pubmed Central) - May 25, 2019
RRM2-siRNAs or Triapine significantly inhibited the cell growth by inducing G0/G1 cell cycle arrest in RCC cells through the attenuation of dNTP pool. The current results provided evidence that RRM2 might act as a novel target for ccRCC, and exploration of nonnucleoside, reversible, small-molecule inhibitors against RRM2 could be promising.
- | Triapine (3-AP) / Vion
Enrollment open, Combination therapy, Metastases: Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer (clinicaltrials.gov) - Apr 23, 2019
P1, N=64, Recruiting, Sponsor: National Cancer Institute (NCI)
The current results provided evidence that RRM2 might act as a novel target for ccRCC, and exploration of nonnucleoside, reversible, small-molecule inhibitors against RRM2 could be promising. Suspended --> Recruiting
- | Recentin (cediranib) / AstraZeneca, Triapine (3-AP) / Vion, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Journal, BRCA Biomarker, PARP Biomarker: Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer. (Pubmed Central) - Apr 17, 2019
Furthermore, we identified that cediranib abrogated pro-survival and anti-apoptotic AKT signaling, thereby enhancing the efficacy of triapine and olaparib against BRCA-wild type EOC cells. Taken together, our results demonstrate a proof-of-principle approach and the combination regiment holds promise in treating BRCA-wild type and PARP inhibitor-resistant EOC.
- | Triapine (3-AP) / Vion, Northwestern University
Phase classification, Enrollment change, Trial primary completion date, Combination therapy, Metastases: NRG-GY006: Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (clinicaltrials.gov) - Apr 9, 2019
P3, N=348, Recruiting, Sponsor: National Cancer Institute (NCI)
Taken together, our results demonstrate a proof-of-principle approach and the combination regiment holds promise in treating BRCA-wild type and PARP inhibitor-resistant EOC. Phase classification: P2 --> P3 | N=188 --> 348 | Trial primary completion date: Sep 2018 --> Jul 2023
- | Triapine (3-AP) / Vion
Trial primary completion date, Combination therapy, Metastases: Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer (clinicaltrials.gov) - Jan 2, 2019
P1, N=64, Suspended, Sponsor: National Cancer Institute (NCI)
Phase classification: P2 --> P3 | N=188 --> 348 | Trial primary completion date: Sep 2018 --> Jul 2023 Trial primary completion date: Dec 2018 --> Dec 2021
- | Triapine (3-AP) / Vion
Journal: Triapine Radiochemotherapy in Advanced Stage Cervical Cancer. (Pubmed Central) - Jun 7, 2018
P3
New trial results and review presented here suggest that a triapine-cisplatin-radiation combination may offer molecular cell cycle target control to maximize damage in cancers and to minimize injury to normal cells. A randomized trial now accrues patients with regionally advanced stage cervical cancer to evaluate triapine's contribution to clinical benefit after cisplatin-radiation (clinicaltrials.gov, NCT02466971).
- | Triapine (3-AP) / Vion
Preclinical, Journal: LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma. (Pubmed Central) - May 31, 2018
The assay was linear from 3 to 3,000ng/mL and proved to be accurate (97.1-103.1%) and precise (<7.4% CV), and met the U.S. FDA guidance for bioanalytical method validation. This LC-MS/MS assay will be an essential tool to further define the pharmacokinetics and oral bioavailability of triapine.
- | Triapine (3-AP) / Vion
Clinical, Journal: Editorial: New Approaches to Radiation-Therapeutic Agent Cancer Care for Women. (Pubmed Central) - Feb 24, 2018
This LC-MS/MS assay will be an essential tool to further define the pharmacokinetics and oral bioavailability of triapine. No abstract available
- | Triapine (3-AP) / Vion, Northwestern University
Trial initiation date, Trial suspension, Combination therapy, Metastases: NRG-GY006: Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (clinicaltrials.gov) - Jan 8, 2018
P2, N=188, Suspended, Sponsor: National Cancer Institute (NCI)
No abstract available Initiation date: Aug 2017 --> Jan 2016 | Recruiting --> Suspended
- | Triapine (3-AP) / Vion, Northwestern University
Trial initiation date, Combination therapy, Metastases: NRG-GY006: Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (clinicaltrials.gov) - Sep 8, 2017
P2, N=188, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Aug 2017 --> Jan 2016 | Recruiting --> Suspended Initiation date: Jan 2016 --> Aug 2017
- | Triapine (3-AP) / Vion
Trial completion, Trial primary completion date, Combination therapy, Surgery, Metastases: 3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Aug 18, 2017
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: Jan 2016 --> Aug 2017 Active, not recruiting --> Completed | Trial primary completion date: May 2011 --> Dec 2012
- | Triapine (3-AP) / Vion
Journal: Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies. (Pubmed Central) - Jun 4, 2017
P1
The triapine-cisplatin combination may be given safely in patients with advanced-stage solid tumor malignancies. On the basis of these results, a phase I trial adequately powered to evaluate oral triapine bioavailability in women with advanced-stage uterine cervix or vulvar cancers is underway.
- | Triapine (3-AP) / Vion, Northwestern University
Combination therapy, Metastases: NRG-GY006: Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (clinicaltrials.gov) - May 19, 2017
P2, N=188, Recruiting, Sponsor: National Cancer Institute (NCI)
On the basis of these results, a phase I trial adequately powered to evaluate oral triapine bioavailability in women with advanced-stage uterine cervix or vulvar cancers is underway. Suspended --> Recruiting
- | Triapine (3-AP) / Vion, Northwestern University
Combination therapy, Metastases: NRG-GY006: Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (clinicaltrials.gov) - May 17, 2017
P2, N=188, Suspended, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Recruiting --> Suspended
- | Triapine (3-AP) / Vion
Journal: Phase I Trial of Triapine-Cisplatin-Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers. (Pubmed Central) - Apr 21, 2017
The combination regimen of triapine-cisplatin-paclitaxel resulted in no objective responses; however, five (83%) of six patients treated at the MTD had stable disease between 1 and 8 months duration. This phase I study showed that the combination regimen of triapine-cisplatin-paclitaxel was safe and provides a rational basis for a follow-up phase II trial to evaluate efficacy and progression-free survival in women with metastatic or recurrent uterine cervix cancer.
- Triapine (3-AP) / Vion
Trial suspension, Combination therapy, IO biomarker, Metastases: Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer (clinicaltrials.gov) - Oct 28, 2016
P1, N=64, Suspended, Sponsor: National Cancer Institute (NCI)
This phase I study showed that the combination regimen of triapine-cisplatin-paclitaxel was safe and provides a rational basis for a follow-up phase II trial to evaluate efficacy and progression-free survival in women with metastatic or recurrent uterine cervix cancer. Recruiting --> Suspended
- Triapine (3-AP) / Vion
Enrollment change, Combination therapy, IO biomarker, Metastases: Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer (clinicaltrials.gov) - Jul 1, 2016
P1, N=64, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended N=48 --> 64
- Triapine (3-AP) / Vion
Enrollment open, Trial initiation date, Combination therapy, IO biomarker, Metastases: Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer (clinicaltrials.gov) - Jun 2, 2016
P1, N=48, Recruiting, Sponsor: National Cancer Institute (NCI)
N=48 --> 64 Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> May 2016
- Triapine (3-AP) / Vion
Enrollment closed, Enrollment change: Cisplatin and Radiation Therapy With or Without Triapine in Treating Patients With Previously Untreated Stage IB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer (clinicaltrials.gov) - Jan 27, 2016
P2, N=25, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> May 2016 Recruiting --> Active, not recruiting | N=73 --> 25
- Triapine (3-AP) / Vion, Northwestern University
Combination therapy, Metastases: NRG-GY006: Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (clinicaltrials.gov) - Jan 26, 2016
P2, N=178, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=73 --> 25 Not yet recruiting --> Recruiting | Initiation date: Jun 2015 --> Jan 2016
- Triapine (3-AP) / Vion
Enrollment change, Combination therapy, Surgery, Metastases: 3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Dec 9, 2015
P1, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Jun 2015 --> Jan 2016 N=12 --> 30
- Triapine (3-AP) / Vion
New P1 trial, Combination therapy, IO biomarker, Metastases: Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer (clinicaltrials.gov) - Nov 5, 2015
P1, N=48, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- Triapine (3-AP) / Vion
Enrollment open: Cisplatin and Radiation Therapy With or Without Triapine in Treating Patients With Previously Untreated Stage IB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer (clinicaltrials.gov) - Oct 23, 2015
P2, N=73, Recruiting, Sponsor: National Cancer Institute (NCI)
N=12 --> 30 Active, not recruiting --> Recruiting
- Triapine (3-AP) / Vion
Enrollment closed, Enrollment change: Cisplatin and Radiation Therapy With or Without Triapine in Treating Patients With Previously Untreated Stage IB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer (clinicaltrials.gov) - Oct 1, 2015
P2, N=5, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | N=73 --> 5
- Triapine (3-AP) / Vion
Enrollment change, Combination therapy: Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer (clinicaltrials.gov) - Sep 30, 2015
P2, N=33, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=73 --> 5 N=78 --> 33
- Triapine (3-AP) / Vion
Trial completion, Combination therapy, Metastases: 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Aug 13, 2015
P2, N=26, Completed, Sponsor: University Health Network, Toronto
N=78 --> 33 Active, not recruiting --> Completed
- | Triapine (3-AP) / Vion, Northwestern University
New P2 trial, Combination therapy, Metastases: NRG-GY006: Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (clinicaltrials.gov) - Jun 9, 2015
P2, N=178, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- Triapine (3-AP) / Vion
Trial primary completion date: Cisplatin and Radiation Therapy With or Without Triapine in Treating Patients With Previously Untreated Stage IB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer (clinicaltrials.gov) - Nov 11, 2014
P2, N=73, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Jun 2015
- Triapine (3-AP) / Vion
Enrollment change, Combination therapy, Surgery, Metastases: 3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Mar 18, 2014
P1, N=12, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2014 --> Jun 2015 N=30 --> 12
- | Triapine (3-AP) / Vion
Trial completion, Combination therapy, Metastases: Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=36, Completed, Sponsor: National Cancer Institute (NCI)
N=30 --> 12 Active, not recruiting --> Completed
- | Triapine (3-AP) / Vion, Northwestern University
Trial completion, Combination therapy: 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=48, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Triapine (3-AP) / Vion
Trial completion, Combination therapy, Metastases: 3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=36, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Triapine (3-AP) / Vion
Trial completion: 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 22, 2014
P1, N=0, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Triapine (3-AP) / Vion
Trial completion, Combination therapy, Metastases: 3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction (clinicaltrials.gov) - Feb 22, 2014
P2, N=39, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Triapine (3-AP) / Vion
Trial completion, Metastases: 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=31, Completed, Sponsor: Cancer Therapeutics Research Group
Active, not recruiting --> Completed Active, not recruiting --> Completed